These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 30337273)

  • 1. Safety, tolerability, and preliminary efficacy of an IGF-1 mimetic in patients with spinal and bulbar muscular atrophy: a randomised, placebo-controlled trial.
    Grunseich C; Miller R; Swan T; Glass DJ; El Mouelhi M; Fornaro M; Petricoul O; Vostiar I; Roubenoff R; Meriggioli MN; Kokkinis A; Guber RD; Budron MS; Vissing J; Soraru G; Mozaffar T; Ludolph A; Kissel JT; Fischbeck KH;
    Lancet Neurol; 2018 Dec; 17(12):1043-1052. PubMed ID: 30337273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial.
    Katsuno M; Banno H; Suzuki K; Takeuchi Y; Kawashima M; Yabe I; Sasaki H; Aoki M; Morita M; Nakano I; Kanai K; Ito S; Ishikawa K; Mizusawa H; Yamamoto T; Tsuji S; Hasegawa K; Shimohata T; Nishizawa M; Miyajima H; Kanda F; Watanabe Y; Nakashima K; Tsujino A; Yamashita T; Uchino M; Fujimoto Y; Tanaka F; Sobue G;
    Lancet Neurol; 2010 Sep; 9(9):875-84. PubMed ID: 20691641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trial.
    Fernández-Rhodes LE; Kokkinis AD; White MJ; Watts CA; Auh S; Jeffries NO; Shrader JA; Lehky TJ; Li L; Ryder JE; Levy EW; Solomon BI; Harris-Love MO; La Pean A; Schindler AB; Chen C; Di Prospero NA; Fischbeck KH
    Lancet Neurol; 2011 Feb; 10(2):140-7. PubMed ID: 21216197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study protocol for the MEXiletine hydrochloride administration trial: a placebo-controlled, randomised, double-blind, multicentre, crossover study of its efficacy and safety in spinal and bulbar muscular atrophy (MEXPRESS).
    Yamada S; Hashizume A; Hijikata Y; Inagaki T; Ito D; Kinoshita F; Nakatochi M; Kobayashi Y; Hirakawa A; Nakamura T; Katsuno M
    BMJ Open; 2018 Sep; 8(9):e023041. PubMed ID: 30206090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial.
    Mercuri E; Deconinck N; Mazzone ES; Nascimento A; Oskoui M; Saito K; Vuillerot C; Baranello G; Boespflug-Tanguy O; Goemans N; Kirschner J; Kostera-Pruszczyk A; Servais L; Gerber M; Gorni K; Khwaja O; Kletzl H; Scalco RS; Staunton H; Yeung WY; Martin C; Fontoura P; Day JW;
    Lancet Neurol; 2022 Jan; 21(1):42-52. PubMed ID: 34942136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of leuprorelin acetate for subjects with spinal and bulbar muscular atrophy: pooled analyses of two randomized-controlled trials.
    Hashizume A; Katsuno M; Suzuki K; Banno H; Takeuchi Y; Kawashima M; Suga N; Mano T; Araki A; Hijikata Y; Hirakawa A; Sobue G;
    J Neurol; 2019 May; 266(5):1211-1221. PubMed ID: 30847645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial.
    Bertini E; Dessaud E; Mercuri E; Muntoni F; Kirschner J; Reid C; Lusakowska A; Comi GP; Cuisset JM; Abitbol JL; Scherrer B; Ducray PS; Buchbjerg J; Vianna E; van der Pol WL; Vuillerot C; Blaettler T; Fontoura P;
    Lancet Neurol; 2017 Jul; 16(7):513-522. PubMed ID: 28460889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
    Maher TM; Corte TJ; Fischer A; Kreuter M; Lederer DJ; Molina-Molina M; Axmann J; Kirchgaessler KU; Samara K; Gilberg F; Cottin V
    Lancet Respir Med; 2020 Feb; 8(2):147-157. PubMed ID: 31578169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.
    Loomba R; Morgan E; Watts L; Xia S; Hannan LA; Geary RS; Baker BF; Bhanot S
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):829-838. PubMed ID: 32553151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.
    Viney NJ; van Capelleveen JC; Geary RS; Xia S; Tami JA; Yu RZ; Marcovina SM; Hughes SG; Graham MJ; Crooke RM; Crooke ST; Witztum JL; Stroes ES; Tsimikas S
    Lancet; 2016 Nov; 388(10057):2239-2253. PubMed ID: 27665230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.
    Lublin F; Miller DH; Freedman MS; Cree BAC; Wolinsky JS; Weiner H; Lubetzki C; Hartung HP; Montalban X; Uitdehaag BMJ; Merschhemke M; Li B; Putzki N; Liu FC; Häring DA; Kappos L;
    Lancet; 2016 Mar; 387(10023):1075-1084. PubMed ID: 26827074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: a multisite, randomised, double-blind, placebo-controlled trial.
    Groome MJ; Fairlie L; Morrison J; Fix A; Koen A; Masenya M; Jose L; Madhi SA; Page N; McNeal M; Dally L; Cho I; Power M; Flores J; Cryz S
    Lancet Infect Dis; 2020 Jul; 20(7):851-863. PubMed ID: 32251641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial.
    Hanna MG; Badrising UA; Benveniste O; Lloyd TE; Needham M; Chinoy H; Aoki M; Machado PM; Liang C; Reardon KA; de Visser M; Ascherman DP; Barohn RJ; Dimachkie MM; Miller JAL; Kissel JT; Oskarsson B; Joyce NC; Van den Bergh P; Baets J; De Bleecker JL; Karam C; David WS; Mirabella M; Nations SP; Jung HH; Pegoraro E; Maggi L; Rodolico C; Filosto M; Shaibani AI; Sivakumar K; Goyal NA; Mori-Yoshimura M; Yamashita S; Suzuki N; Katsuno M; Murata K; Nodera H; Nishino I; Romano CD; Williams VSL; Vissing J; Auberson LZ; Wu M; de Vera A; Papanicolaou DA; Amato AA;
    Lancet Neurol; 2019 Sep; 18(9):834-844. PubMed ID: 31397289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with Creatine Monohydrate in Spinal and Bulbar Muscular Atrophy: Protocol for a Randomized, Double-Blind, Placebo-Controlled Trial.
    Hijikata Y; Katsuno M; Suzuki K; Hashizume A; Araki A; Yamada S; Inagaki T; Ito D; Hirakawa A; Kinoshita F; Gosho M; Sobue G
    JMIR Res Protoc; 2018 Mar; 7(3):e69. PubMed ID: 29506970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of bimagrumab on thigh muscle volume and composition in men with casting-induced atrophy.
    Rooks DS; Laurent D; Praestgaard J; Rasmussen S; Bartlett M; Tankó LB
    J Cachexia Sarcopenia Muscle; 2017 Oct; 8(5):727-734. PubMed ID: 28905498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CAL02, a novel antitoxin liposomal agent, in severe pneumococcal pneumonia: a first-in-human, double-blind, placebo-controlled, randomised trial.
    Laterre PF; Colin G; Dequin PF; Dugernier T; Boulain T; Azeredo da Silveira S; Lajaunias F; Perez A; François B
    Lancet Infect Dis; 2019 Jun; 19(6):620-630. PubMed ID: 31056427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-blind, placebo-controlled, randomised withdrawal phase 2a trial.
    Zakrzewska JM; Palmer J; Morisset V; Giblin GM; Obermann M; Ettlin DA; Cruccu G; Bendtsen L; Estacion M; Derjean D; Waxman SG; Layton G; Gunn K; Tate S;
    Lancet Neurol; 2017 Apr; 16(4):291-300. PubMed ID: 28216232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial.
    Brightling CE; Chanez P; Leigh R; O'Byrne PM; Korn S; She D; May RD; Streicher K; Ranade K; Piper E
    Lancet Respir Med; 2015 Sep; 3(9):692-701. PubMed ID: 26231288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study.
    Reuter U; Goadsby PJ; Lanteri-Minet M; Wen S; Hours-Zesiger P; Ferrari MD; Klatt J
    Lancet; 2018 Nov; 392(10161):2280-2287. PubMed ID: 30360965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial.
    Huntington Study Group Reach2HD Investigators
    Lancet Neurol; 2015 Jan; 14(1):39-47. PubMed ID: 25467848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.